4DMedical Limited (ASX:4DX) Partners with Olympus to Launch SeleCT™ Screening Campaign
Partnership Details
Olympus Corporation has launched a new SeleCT™ Screening campaign across the United States, utilizing 4DMedical’s lung density analysis technology on existing CT scans to identify candidates for the Olympus Spiration™ Valve System.
Commercial and Clinical Significance
The full market release establishes Olympus as a key channel partner, scales 4DMedical’s AI-based lung imaging across major U.S. health systems, and reinforces the company’s role in early detection and therapy enablement for emphysema.
Executive Comments
4DMedical MD/CEO and Founder Andreas Fouras stated, “This campaign by Olympus represents a significant investment into our partnership with them. Through our combined efforts we are delivering real-world impact at scale—enhancing diagnosis, guiding therapy, and ultimately improving outcomes for patients living with emphysema.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
